Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
02
01
2019
revised:
17
04
2019
accepted:
10
07
2019
pubmed:
31
8
2019
medline:
25
9
2020
entrez:
31
8
2019
Statut:
ppublish
Résumé
The incidence of esophageal adenocarcinoma has risen dramatically over the past half century, and the underlying reasons are incompletely understood. Broad shifts to the upper gastrointestinal microbiome may be partly responsible. The goal of this study was to describe alterations in the esophageal microbiome that occur with progression from Barrett's esophagus to esophageal adenocarcinoma. A case-control study was performed of patients with and without Barrett's esophagus who were scheduled to undergo upper endoscopy. Demographic, clinical, and dietary intake data were collected, and esophageal brushings were collected during the endoscopy. 16S rRNA gene sequencing was performed to characterize the microbiome. A total of 45 patients were enrolled and included in the analyses [16 controls; 14 Barrett's esophagus without dysplasia (NDBE); 6 low-grade dysplasia (LGD); 5 high-grade dysplasia (HGD); and 4 esophageal adenocarcinoma]. There was no difference in alpha diversity between non-Barrett's esophagus and Barrett's esophagus, but there was evidence of decreased diversity in patients with esophageal adenocarcinoma as assessed by Simpson index. There was an apparent shift in composition at the transition from LGD to HGD, and patients with HGD and esophageal adenocarcinoma had decreased Firmicutes and increased Proteobacteria. In addition, patients with HGD or esophageal adenocarcinoma had increased Shifts in the Barrett's esophagus-associated microbiome were observed in patients with HGD and esophageal adenocarcinoma, with increases in certain potentially pathogenic bacteria. The microbiome may play a role in esophageal carcinogenesis.
Sections du résumé
BACKGROUND
The incidence of esophageal adenocarcinoma has risen dramatically over the past half century, and the underlying reasons are incompletely understood. Broad shifts to the upper gastrointestinal microbiome may be partly responsible. The goal of this study was to describe alterations in the esophageal microbiome that occur with progression from Barrett's esophagus to esophageal adenocarcinoma.
METHODS
A case-control study was performed of patients with and without Barrett's esophagus who were scheduled to undergo upper endoscopy. Demographic, clinical, and dietary intake data were collected, and esophageal brushings were collected during the endoscopy. 16S rRNA gene sequencing was performed to characterize the microbiome.
RESULTS
A total of 45 patients were enrolled and included in the analyses [16 controls; 14 Barrett's esophagus without dysplasia (NDBE); 6 low-grade dysplasia (LGD); 5 high-grade dysplasia (HGD); and 4 esophageal adenocarcinoma]. There was no difference in alpha diversity between non-Barrett's esophagus and Barrett's esophagus, but there was evidence of decreased diversity in patients with esophageal adenocarcinoma as assessed by Simpson index. There was an apparent shift in composition at the transition from LGD to HGD, and patients with HGD and esophageal adenocarcinoma had decreased Firmicutes and increased Proteobacteria. In addition, patients with HGD or esophageal adenocarcinoma had increased
CONCLUSIONS
Shifts in the Barrett's esophagus-associated microbiome were observed in patients with HGD and esophageal adenocarcinoma, with increases in certain potentially pathogenic bacteria.
IMPACT
The microbiome may play a role in esophageal carcinogenesis.
Identifiants
pubmed: 31466948
pii: 1055-9965.EPI-19-0008
doi: 10.1158/1055-9965.EPI-19-0008
pmc: PMC6774849
mid: NIHMS1534988
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1687-1693Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK111847
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI116939
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA163004
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Mayo Clin Proc. 1994 Jun;69(6):539-47
pubmed: 8189759
J Infect Dis. 1993 Jul;168(1):219-21
pubmed: 8515114
Cell Host Microbe. 2015 Oct 14;18(4):489-500
pubmed: 26468751
Nat Med. 2015 Jul;21(7):808-14
pubmed: 26053625
Gut. 2014 Dec;63(12):1932-42
pubmed: 24658599
PLoS One. 2015 May 28;10(5):e0128346
pubmed: 26020633
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
Clin Cancer Res. 2012 Apr 15;18(8):2138-44
pubmed: 22344232
PLoS One. 2015 Jun 15;10(6):e0129055
pubmed: 26076489
MBio. 2018 Mar 20;9(2):
pubmed: 29559578
Clin Transl Gastroenterol. 2018 Oct 25;9(10):199
pubmed: 30356041
Gut. 1998 Sep;43(3):327-33
pubmed: 9863476
Gastroenterology. 2014 May;146(6):1534-1546.e3
pubmed: 24406471
Lancet Gastroenterol Hepatol. 2017 Jan;2(1):32-42
pubmed: 28404012
Aliment Pharmacol Ther. 2013 Jun;37(11):1084-92
pubmed: 23600758
Cell Host Microbe. 2010 Sep 16;8(3):292-300
pubmed: 20833380
Cancer Prev Res (Phila). 2008 Oct;1(5):329-38
pubmed: 19138977
Microbiome. 2015 Jun 01;3:23
pubmed: 26034601
Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):732-7
pubmed: 16407106
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
Annu Rev Microbiol. 2016 Sep 8;70:395-411
pubmed: 27607555
Clin Transl Gastroenterol. 2018 Feb 20;9(3):135
pubmed: 29491399
Gastroenterology. 2009 Aug;137(2):588-97
pubmed: 19394334
Inflamm Bowel Dis. 2015 Jun;21(6):1219-28
pubmed: 25844959
Gut Microbes. 2014;5(5):675-80
pubmed: 25483338
Microb Pathog. 2017 May;106:171-181
pubmed: 26875998
Sci Transl Med. 2016 May 18;8(339):339ra71
pubmed: 27194729
Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2450-6
pubmed: 21930957
Appl Environ Microbiol. 2005 Dec;71(12):8228-35
pubmed: 16332807
Science. 2018 Feb 2;359(6375):592-597
pubmed: 29420293
PLoS One. 2010 Mar 10;5(3):e9490
pubmed: 20224823
World J Gastroenterol. 2010 Sep 7;16(33):4135-44
pubmed: 20806429
Nat Biotechnol. 2013 Sep;31(9):814-21
pubmed: 23975157
Dig Dis Sci. 2010 Jul;55(7):1911-7
pubmed: 19830561
Public Health Nutr. 2004 Dec;7(8):1097-105
pubmed: 15548349
Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1012-23
pubmed: 25931440
J Am Diet Assoc. 2005 Mar;105(3):352-63; quiz 487
pubmed: 15746822
Gastroenterology. 2015 Oct;149(4):883-5.e9
pubmed: 26164495
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4250-5
pubmed: 15016918
Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):183-6
pubmed: 21127287